Key facts
- This page summarizes Daniel A. Yerace's Form 4 filing for Coeptis Therapeutics Holdings, Inc. (COEP).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 06 Mar 2025, 17:29.
Daniel A. Yerace - 04 Mar 2025 Form 4 Insider Report for Coeptis Therapeutics Holdings, Inc. (COEP)
- Reporting relationship
- VP of Operations, Director
- Issuer ticker
- COEP
- Reported as of
- 04 Mar 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 06 Mar 2025, 17:29:34 UTC
- Prior SEC filing
- 09 Jan 2024
- Next SEC filing
- 13 Feb 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Daniel A. Yerace
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Daniel A. Yerace filed Form 4 for Coeptis Therapeutics Holdings, Inc. (COEP) on 06 Mar 2025.
Change
- Previous filing in this sequence was filed on 09 Jan 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
COEP
transaction
Derivative
Non-Qualified Stock Options (right to buy)
Award
- Transaction value
- Shares
- +5,000
- Change %
- +25%
- Price
- Shares after
- 25,000
- Date
- 04 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,000
- Exercise price
- $10.56
- Footnotes
- F1, F2, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
On March 4, 2025, the reporting person received a grant of 5,000 non-qualified stock options, under the 2022 equity incentive plan.
Footnote F2
The exercise price is the FMV of the shares, which is equal to the Company's stock price on the Nasdaq Capital Market on the day of grant.
Footnote F3
Options will vest over 4 years, in equal quarterly installments over such period, with the final options vesting on 12/31/28.
Footnote F4
Expiration date is ten years from the day of grant.